CG Oncology, Inc. Common stock Income Statement
Concept
Total Revenue
YoY
Cost of Goods Sold (COGS)
Gross Profit
Operating expenses
Selling, General & Administrative
Research & Development
Operating Income
Interest Expense
Income Before Tax
Tax Provision
Net Income
YoY
Total Expenses
Net Interest Income
EBITDA
Reconciled Depreciation
EBIT
2023
2022
2021
0M
6.81%
0M
0M
56M
10M
46M
-55M
0M
-49M
0M
-49M
37.14%
0M
7M
0M
0M
0M
0M
-98.16%
0M
0M
35M
6M
29M
-35M
0M
-35M
0M
-35M
176.06%
0M
0M
0M
0M
0M
10M
-
0M
0M
23M
5M
18M
-13M
0M
-13M
0M
-13M
176.06%
0M
0M
0M
0M
0M
Concept
Total Revenue
YoY
Cost of Goods Sold (COGS)
Gross Profit
Operating expenses
Selling, General & Administrative
Research & Development
Operating Income
Interest Expense
Income Before Tax
Tax Provision
Net Income
YoY
Total Expenses
Net Interest Income
EBITDA
Reconciled Depreciation
EBIT
4Q2023
4Q2022
0M
-
0M
0M
19M
3M
16M
-19M
0M
-16M
0M
-16M
176.06%
0M
3M
0M
0M
0M
0M
-
0M
0M
9M
2M
8M
-9M
0M
-8M
0M
-8M
176.06%
0M
1M
0M
0M
0M